Brickell Biotech EBIT

Brickell Biotech (BBI) currently reports a EBIT of $-31M as of June 2022. That compares with $-32M in the prior-year period — up 5.6% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Brickell Biotech's EBIT history and peer comparisons.

Brickell Biotech's EBIT increased from $-32M to $-31M — a 5.6% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Brickell Biotech's EBIT of $-31M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Brickell Biotech reported $-31M in EBIT as of June 2022. That compares with $-32M in the prior-year period — up 5.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Brickell Biotech, and consider following BBI for alerts when major investors trade the stock.